A retrospective chart review of the use of olanzapine for the prevention of delayed emesis in cancer patients

Journal of Pain and Symptom Management

Volumn 25, Issue 5, 2003, Pages 485-488

  Passik, Steven D ^a,c   Kirsh, Kenneth L ^a   Theobald, Dale E ^b   Dickerson, Pamela ^b   Trowbridge, Randall ^b   Gray, David ^b   Beaver, Megan ^b   Comparet, Jessica ^b   Brown, Justin ^b  

^a UNIVERSITY OF KENTUCKY   (United States)

^b Oncology Symptom Control Research   (United States)

^c UNIVERSITY OF KENTUCKY   (United States)

Author keywords

Chemotherapy; Nausea; Olanzapine

Indexed keywords

ANTINEOPLASTIC AGENT; OLANZAPINE;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER; CANCER CENTER; CANCER CHEMOTHERAPY; CANCER PATIENT; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; COLON CANCER; CONTROLLED STUDY; DISEASE SEVERITY; DRUG USE; EDEMA; ELECTRONIC MEDICAL RECORD; ESOPHAGUS CANCER; FEMALE; HUMAN; HYPOTHESIS; INTESTINE CANCER; LUNG CANCER; LYMPHOMA; MALE; MEDICAL RECORD; MORBIDITY; NAUSEA; OVARY CANCER; PANCREAS CANCER; PATIENT SELECTION; PLANNING; PROSTATE CANCER; RECTUM CANCER; RESTLESSNESS; RETROSPECTIVE STUDY; SEDATION; SIDE EFFECT; STOMACH CANCER; UTERINE CERVIX CANCER;

EID: 0037405988     PISSN: 08853924     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0885-3924(03)00078-2     Document Type: Article

References (12)

1. Gobert A., Rivet J., Audinot V.et al. Functional correlates of dopamine D3 receptor activation in the rat in vivo and their modulation by the selective antagonist (+) - - S 14297 II. Both D2 and "silent" D3 autorecptors control synthesis and release in mesolimbic, mesocortical and nigrostriatal pathways. J Pharmacol Exp Ther. 275:1995;899-913.
2. Meltzer H., Matsubara S., Lee J. Classification of typical and atypical antipsychotic drugs on the basis of dopamine D-1, D-2, and serotonin 2 pK, values. J Pharmacol Exp Ther. 251:1989;238-246.
3. Roth B., Craigo S., Choudary M.et al. Binding of typical and atypical psychotic agents to 5-hydroxytryptamine-6 and 5-hydroxytryptamine-7 receptors. J Pharmacol Exp Ther. 268:1994;1403-1410.
4. Passik SD, Lundberg J, Kirsh KL, Theobald DE, Donaghy KD, Holtsclaw E, Cooper M, Dugan W. A pilot exploration of the antiemetic activity of olanzapine for the relief of nausea in patients with advanced cancer and pain. Journal of Pain and Symptom Management, 23:526-532.
5. Pisters K., Kris M. Treatment-related nausea and vomiting. Berger A., Portenoy R.K., Weissman D.E. Principles and practice of supportive oncology. 1998;165-177 Lippincott-Raven, Philadelphia.
6. Ward S.E., Goldberg N., Miller-McCauley V.et al. Patient-related barriers to management of cancer pain. Pain. 52:1993;319-324.
7. Sweet R., DeSensi E., Zubenko G. Reliability and applicability of movement disorders rating scales in the elderly. J Neuropsych Clin Neurosci. 5:1993;56-60.
8. Aparasu R., McCoy R., Weber C.et al. Opioid-induced emesis among hospitalized nonsurgical patients. effect on pain and quality of life J Pain Symptom Manage. 18:1999;280-288.
9. Passik S.D., Kirsh K.L., Rosenfeld B., McDonald M., Theobald D. The changeable nature of patients' fears regarding chemotherapy. Implications for palliative care J Pain and Symptom Management. 21:2001;113-120.
10. Pirl W.F., Roth A.J. Remission of chemotherapy-induced emesis with concurrent olanzapine treatment. a case report Psycho-oncol. 9:2000;84-87.
11. Bymaster F., Calligaro D., Falcone J.et al. Radioreceptor binding profile of the atypical antipsychotic olanzapine. Neuropsychopharmacol. 14:1996;87-96.
12. Bymaster F., Falcone J., Bauzon D.et al. Potent antagonism of serotonin (5HT3) and 5HT6 receptors by olanzapine. Euro J Pharm. 430:2001;341-349.